Journal Club

December 2017: EARNEST trial looks at long-term efficacy of second-line ART regimens

December 1, 2017

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.

This article reports on the Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) trial, which compared the efficacy and safety of three second-line antiretroviral therapy (ART) regimens after 144 weeks of follow-up.

Continue Reading »

October/November 2017: HPTN 067/ADAPT-Cape Town results on daily versus non-daily PrEP regimens

November 1, 2017

Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial

This article reports on the results of the HPTN 067/ADAPT-Cape Town Trial, which was an open-label, randomized study that compared daily versus non-daily oral pre-exposure prophylaxis (PrEP) regimens among high-risk women in Cape Town, South Africa.

Continue Reading »